This compound is the E stereoisomer of JIB-04, an inhibitor of Jumonji family histone demethylases; it does not inhibit activity of α-ketoglutarate. JIB-04 exhibits anticancer chemotherapeutic activity, inhibiting protein translation initiation. In cancer models, JIB-04 inhibits cell viability, decreases tumor burden, and increases survival rates.
| Cas No. | 199596-05-9 |
|---|---|
| Purity | ≥98% |
| Formula | C17H13ClN4 |
| Formula Wt. | 308.77 |
| Chemical Name | (E)-N-(5-Chloro-pyridin-2-yl)-N′-(phenyl-pyridin-2-yl-methylene)-hydrazine |
| IUPAC Name | 5-Chloro-2-{(2E)-2-[phenyl(2-pyridinyl)methylene]hydrazino}pyridine |
| Synonym | NSC 693627, JHDM inhibitor VII |
| Solubility | DMSO 25 mg/mL Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Van Rechem C, Black JC, Boukhali M, et al. Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis. Cancer Discov. 2015 Mar;5(3):255-63. PMID: 25564516.
Wang L, Chang J, Varghese D, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun. 2013;4:2035. Erratum in: Nat Commun. 2013;4:2639. PMID: 23792809.
